441715-26-0

Basic information

• Product Name: 6-FLUORO-1-METHYL-1H-INDOLE-3-CARBOXYLIC ACID
• Synonyms: 6-FLUORO-1-METHYL-1H-INDOLE-3-CARBOXYLIC ACID;1H-Indole-3-carboxylic acid, 6-fluoro-1-methyl-
• CAS NO: 441715-26-0
• Molecular Weight: 193.177
• Mol File: 441715-26-0.mol

Chemical Properties

• Boiling Point: 392.0±22.0 °C(Predicted)
• Density: 1.34±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 6-FLUORO-1-METHYL-1H-INDOLE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-1-METHYL-1H-INDOLE-3-CARBOXYLIC ACID(441715-26-0)
• EPA Substance Registry System: 6-FLUORO-1-METHYL-1H-INDOLE-3-CARBOXYLIC ACID(441715-26-0)

Safety Data

• Hazardous Substances Data: 441715-26-0(Hazardous Substances Data)

Upstream product

• 441715-93-1 6-fluoro-1-methyl-1H-indole-3-carbaldehyde 
• 1492020-32-2 C₁₁H₇F₄NO 
• 399-51-9 6-fluoro-1H-indole 
• 441715-92-0 6-fluoro-1-methyl-1H-indole 

Relevant articles and documents

Salicylaldehyde-Promoted Cobalt-Catalyzed C-H/N-H Annulation of Indolyl Amides with Alkynes: Direct Synthesis of a 5-HT3 Receptor Antagonist Analogue

A cobalt-catalyzed annulation of the C(sp2)-H/N-H bond of indoloamides with alkynes assisted by 8-aminoquinoline is reported for the synthesis of six-membered indololactams. The use of salicylaldehyde as the ligand is crucial for this transformation. The protocol has a broad scope for both alkynes and indoles. Preparing an active Co complex illustrates that salicylaldehyde plays a key role in the C-H activation step. The synthetic applications are proven by the gram-scale reaction and one-step construction of the multicyclic 5-HT3 receptor antagonist.

NOVEL INDOLE AND PYRROLOPYRIDINE AMIDES

The present invention relates to indole and pyrrolopyridine amide derivatives of formula (I) wherein R1, R 2, R 3, U, V, W, X, Y, Z and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.